You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌業績》翰森製藥(03692.HK)中期賺12.9億人幣按年跌0.7% 中期息7.07港仙
阿思達克 08-31 17:02
翰森製藥(03692.HK)公布截至今年6月底止中期業績,營業額45.11億元人民幣(下同),按年升1.7%。純利12.89億元,按年跌0.7%;每股盈利0.22元。派中期息7.07港仙,上年同期派5港仙。 期內創新藥銷售收入約27.86億元,按年增長約20.1%,佔收入比例從去年同期的52.3%上升至61.8%。於6月底,獲批上市7款創新藥,其中6款已被納入國家醫保目錄。 上半年研發開支約9.29億元,按年增長25.8%,佔收入比例約20.6%。公司將繼續加大研發投入,強化尖端技術,積極開展外部合作,加速推動自研產品、引進產品的開發和商業化進程,豐富產品管線佈局。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account